Skip to main content

Table 2 Prognostic factors for progression-free survival (PFS) and overall survival (OS) in univariate analysis

From: Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

 

12 months PFS rate [95%CI]

p value

12 months OS rate [95%CI]

p value

Age (years)

 < 65

24.6 [14.1–43.1]

0.01

83.8 [73.4–95.7]

0.3

 ≥ 65

30.8 [17.9–53]

 

89 [80.3–98.75]

 

Performance status

 0–1

36.7 [27.5–49]

0.5

88.8 [82.1–96]

0.05

 2

0

 

56.2 [28.1–100]

 

Grade

 < 3

38.1 [27.6–52.6]

0.2

85.4 [76.9–94.8]

0.7

 ≥ 3

23.2 [10.9–49.1]

 

86.8 [74–100]

 

PR status

 Negative

35.7 [21.4–59.5]

0.5

80.3 [66.1–97.6]

0.1

 Positive

33.8 [23.5–48.7]

 

88.9 [81.3–97.1]

 

Synchronous metastasis

 No

37.7 [27–52.7]

0.05

95.3 [90.3–100]

0.07

 Yes

27.8 [15–51.4]

 

68 [52.7–87.9]

 

Visceral metastasis

 No

39.5 [25.3–61.6]

0.6

80.4 [67.3–96]

0.7

 Yes

27.8 [15–51.4]

 

89.5 [81.8–97.9]

 

Primary endocrine resistance

 No

40.4 [30.3–53.8]

0.02

90.2 [83.5–97.5]

0.01

 Yes

11.8 [3.2–43.2]

 

69 [49.7–95.8]

 

Previous chemotherapy

 No

49.7 [36.2–68.4]

< 0.001

100% - No death

0.01

 1 or 2 lines

35.1 [21.1–58.2]

 

76.6 [62.8–93.6]

 

 ≥ 3 lines

4.8 [0.7–32.2]

 

74.8 [57.8–96.7]

 

pTKa at baseline*

HR = 1.3 [1.2–1.5]

< 0.0001

HR = 1.4 [1.2–1.6]

0.0006

pTKa at 4 weeks*

HR = 1.3 [1.1–1.5]

0.01

HR = 1.5 [1.2–1.8]

0.0003

Variation of pTKa between baseline and 4 weeks

 Increase

30.4 [17.6–52.3]

0.9

75 [60.1–93.7]

0.2

 Decrease

34.2 [22.6–51.6]

 

90.7 [82.4–99.9]

 
  1. *HR for an increase of 10 units of \( \sqrt{\mathrm{pTKa}} \)